[go: up one dir, main page]

DK3360890T3 - GENTERAPHY - Google Patents

GENTERAPHY Download PDF

Info

Publication number
DK3360890T3
DK3360890T3 DK17210269.1T DK17210269T DK3360890T3 DK 3360890 T3 DK3360890 T3 DK 3360890T3 DK 17210269 T DK17210269 T DK 17210269T DK 3360890 T3 DK3360890 T3 DK 3360890T3
Authority
DK
Denmark
Prior art keywords
genteraphy
Prior art date
Application number
DK17210269.1T
Other languages
Danish (da)
Inventor
Tim Funnell
Chris Hollowood
Christian Groendahl
Original Assignee
Syncona Ip Holdco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55130363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3360890(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syncona Ip Holdco Ltd filed Critical Syncona Ip Holdco Ltd
Application granted granted Critical
Publication of DK3360890T3 publication Critical patent/DK3360890T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
DK17210269.1T 2015-10-28 2016-10-27 GENTERAPHY DK3360890T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1519086.1A GB201519086D0 (en) 2015-10-28 2015-10-28 Gene Therapy
EP16788764.5A EP3262066B2 (en) 2015-10-28 2016-10-27 Gene therapy

Publications (1)

Publication Number Publication Date
DK3360890T3 true DK3360890T3 (en) 2020-11-02

Family

ID=55130363

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16788764.5T DK3262066T4 (en) 2015-10-28 2016-10-27 GENE THERAPY
DK17210269.1T DK3360890T3 (en) 2015-10-28 2016-10-27 GENTERAPHY

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16788764.5T DK3262066T4 (en) 2015-10-28 2016-10-27 GENE THERAPY

Country Status (20)

Country Link
US (3) US20190255193A1 (en)
EP (3) EP3360890B1 (en)
JP (3) JP7126944B2 (en)
KR (1) KR20180066247A (en)
CN (4) CN117343960A (en)
AU (3) AU2016344523B2 (en)
BR (1) BR112018008731A8 (en)
CA (1) CA3002125A1 (en)
DK (2) DK3262066T4 (en)
ES (2) ES2828050T3 (en)
GB (1) GB201519086D0 (en)
HK (1) HK1248723B (en)
IL (3) IL284577B2 (en)
MX (1) MX366343B (en)
NO (1) NO3262066T3 (en)
PL (2) PL3360890T3 (en)
RU (1) RU2740038C2 (en)
SG (1) SG11201802934WA (en)
WO (1) WO2017072515A1 (en)
ZA (1) ZA201802462B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102773865B1 (en) * 2015-09-24 2025-03-04 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Compositions and methods for treating complement-mediated diseases
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
WO2017180936A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
ES2985828T3 (en) * 2017-07-31 2024-11-07 Reflection Biotechnologies Ltd Cellular models and therapies for eye diseases
US20210188927A1 (en) * 2017-10-20 2021-06-24 Gemini Therapeutics, Inc. Compositions and methods for treating age-related macular degeneration
JP2022512667A (en) * 2018-10-10 2022-02-07 ウィスコンシン アラムニ リサーチ ファンデーション KIR7.1 Gene Therapy Vector and How to Use It
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
GB201821089D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Codon-optimised complement factor I
EP3946467A1 (en) * 2019-04-03 2022-02-09 REGENXBIO Inc. Gene therapy for eye pathologies
EP4028025A4 (en) * 2019-09-09 2023-07-19 University of Pittsburgh - of the Commonwealth System of Higher Education Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Complement factor i variants, fusion constructs and compositions comprising same and uses thereof
GB202009741D0 (en) 2020-06-25 2020-08-12 Freeline Therapeutics Ltd Polynucleotide
WO2022056531A1 (en) * 2020-09-09 2022-03-17 Homology Medicines, Inc. Vectorized antibodies and uses thereof
EP4238567A4 (en) 2020-10-30 2024-09-04 Keio University NOVEL TREATMENT AND PREVENTION OF SARCOPENIA-RELATED DISEASES
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
WO2023079297A1 (en) 2021-11-04 2023-05-11 Freeline Therapeutics Limited Mutant complement factor i variants with increased activity
US20250161255A1 (en) 2022-01-25 2025-05-22 Motoshi Hayano New therapy and prevention for suppressing aging-related disorders including sarcopenia

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP2058329B1 (en) * 2003-06-10 2010-08-18 NsGene A/S Improved secretion of neublastin
EP2302076B1 (en) * 2005-02-14 2014-11-12 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
CA2626356C (en) * 2005-10-21 2017-08-22 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
BRPI0712987A2 (en) * 2006-06-21 2012-04-10 Musc Found For Res Dev h-factor-targeted disease treatment
WO2008106644A2 (en) * 2007-03-01 2008-09-04 Advanced Vision Therapies, Inc. Treatment of diseases characterized by inflammation
CN101657097A (en) * 2007-03-01 2010-02-24 先进视觉疗法公司 With the inflammation is the treatment of diseases of feature
DK2191001T3 (en) 2007-04-09 2016-09-19 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
GB0816702D0 (en) * 2008-09-12 2008-10-22 Trinity College Dublin Complement proteins
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
TWI702955B (en) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 Treatment of amd using aav sflt-1
EP2948480A4 (en) * 2013-01-23 2016-12-07 Musc Found For Res Dev NATURAL ANTIBODY TARGETING CONSTRUCTS AND USES THEREOF
US20140234275A1 (en) * 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
SG10201912901YA (en) * 2013-04-17 2020-02-27 Genzyme Corp Compositions and methods for treating and preventing macular degeneration
ES2716615T3 (en) * 2013-06-28 2019-06-13 Inst Nat Sante Rech Med Methods for expressing a polynucleotide of interest in the retina of a subject
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
GB201519086D0 (en) * 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders

Also Published As

Publication number Publication date
AU2016344523B2 (en) 2022-03-17
WO2017072515A1 (en) 2017-05-04
MX2018005145A (en) 2018-08-09
AU2022203675A1 (en) 2022-06-16
AU2016344523A1 (en) 2018-06-14
BR112018008731A8 (en) 2020-03-31
IL304084A (en) 2023-08-01
IL258806B (en) 2021-07-29
HK1248723B (en) 2019-11-22
IL284577B1 (en) 2023-08-01
IL304084B1 (en) 2025-11-01
JP2022141670A (en) 2022-09-29
CN108431030B (en) 2023-10-20
EP3360890A1 (en) 2018-08-15
ZA201802462B (en) 2021-01-27
JP2018537122A (en) 2018-12-20
RU2018118954A (en) 2019-12-02
ES2666204T5 (en) 2023-11-03
DK3262066T4 (en) 2023-08-21
NO3262066T3 (en) 2018-07-07
EP3262066B2 (en) 2023-06-07
RU2740038C2 (en) 2020-12-30
US20250319210A1 (en) 2025-10-16
IL258806A (en) 2018-06-28
IL284577A (en) 2021-08-31
CN117343960A (en) 2024-01-05
BR112018008731A2 (en) 2018-11-06
SG11201802934WA (en) 2018-05-30
CN116271104A (en) 2023-06-23
JP2024156706A (en) 2024-11-06
CA3002125A1 (en) 2017-05-04
EP3262066A1 (en) 2018-01-03
PL3360890T3 (en) 2020-12-28
ES2666204T3 (en) 2018-05-03
CN116370655A (en) 2023-07-04
CN108431030A (en) 2018-08-21
IL284577B2 (en) 2023-12-01
US20230277689A1 (en) 2023-09-07
PL3262066T3 (en) 2018-07-31
EP3786176A1 (en) 2021-03-03
PL3262066T5 (en) 2023-10-30
ES2828050T3 (en) 2021-05-25
JP7126944B2 (en) 2022-08-29
MX366343B (en) 2019-07-05
EP3360890B1 (en) 2020-10-07
EP3262066B1 (en) 2018-02-07
GB201519086D0 (en) 2015-12-09
RU2018118954A3 (en) 2020-03-13
KR20180066247A (en) 2018-06-18
DK3262066T3 (en) 2018-05-22
AU2025200979A1 (en) 2025-03-06
US20190255193A1 (en) 2019-08-22
AU2022203675B2 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
DK3283625T3 (en) NUCLEASE-MEDIED GENOMEDITING
DK3331869T3 (en) MUSCARINAGONISTS
DK3277719T3 (en) POLYPEPTIDER
DK3331528T3 (en) MUSCARINAGONISTS
EP3316375A4 (en) REDOXDURCHFLUSSZELLE
DK3305788T3 (en) JANUS-KINASE-HIMMER
DK3360890T3 (en) GENTERAPHY
DK3331529T3 (en) MUSCARINAGONISTS
DK3310450T3 (en) OIL-WATER-SEPARATOR
EP3290364A4 (en) FÖRDERBANDVERSCHLEISSÜBERWACHUNGSSYSTEM
DK3270930T3 (en) PRE-CLAMPSY
EP3381654A4 (en) FLÜSSIGBLASFORMVERFAHREN
DK3394281T3 (en) GÆRCELLLE
EP3363322A4 (en) HAARVERLÄNGERER
DK3292136T3 (en) PENICILLIN-G-ACYLASER
DE112015006486A5 (en) Inkubationsrinne
EP3548009A4 (en) POLYMANANOPARTICLE
DK3274482T3 (en) STENBORSKNOP
EP3377179A4 (en) EPI-743 DEUTTERATED
DE102015206660A8 (en) Beamsaw
DK3318308T3 (en) BATHMIN TONKETS
DE112015005898A5 (en) Gurtschlossbringer
DE112016005599A5 (en) grillers
EP3353789A4 (en) SPINRAM
EP3307242A4 (en) PICN-01